Is this the end of the ultrathin-strut hypothesis?
作者信息
Bangalore Sripal, Finn Aloke V
机构信息
Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
CVPath Institute, Gaithersburg, MD, USA.
出版信息
EuroIntervention. 2024 May 20;20(10):e625-e626. doi: 10.4244/EIJ-E-24-00017.
Abstract
摘要
相似文献
1
Is this the end of the ultrathin-strut hypothesis?超薄支柱假说就此终结了吗？
EuroIntervention. 2024 May 20;20(10):e625-e626. doi: 10.4244/EIJ-E-24-00017.
2
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.经皮冠状动脉介入治疗中小血管病变患者应用超薄壁支架与薄壁药物洗脱支架的长期疗效：BIOSCIENCE 随机试验的亚组分析。
Circ Cardiovasc Interv. 2019 Aug;12(8):e008024. doi: 10.1161/CIRCINTERVENTIONS.119.008024. Epub 2019 Aug 6.
3
Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial.高出血风险 PCI 患者中使用超薄-与薄壁支架的比较：来自 COMPARE 60/80 HBR 试验的结果：一项开放标签、随机、对照试验。
Circ Cardiovasc Interv. 2024 Oct;17(10):e014042. doi: 10.1161/CIRCINTERVENTIONS.123.014042. Epub 2024 Oct 1.
4
Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes.新一代超薄支架与厚壁支架药物洗脱支架在慢性和急性冠状动脉综合征中的差异效应。
JACC Cardiovasc Interv. 2021 Nov 22;14(22):2461-2473. doi: 10.1016/j.jcin.2021.09.028.
5
Treatment of in-stent restenosis with ultrathin-strut versus thin-strut drug-eluting stents or drug-eluting balloons: a multicentre registry.采用超薄支架与薄支架药物洗脱支架或药物洗脱球囊治疗支架内再狭窄：一项多中心注册研究。
EuroIntervention. 2024 Nov 4;20(21):e1340-e1354. doi: 10.4244/EIJ-D-24-00491.
6
Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects.超细支撑与细支撑支架在临床前和临床研究对象中的愈合情况及结果
EuroIntervention. 2024 May 20;20(10):e669-e680. doi: 10.4244/EIJ-D-23-00563.
7
Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents.薄型、极薄型或超薄型药物洗脱支架，采用生物可降解或耐用聚合物涂层。
Curr Opin Cardiol. 2020 Nov;35(6):705-711. doi: 10.1097/HCO.0000000000000786.
8
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.超薄型与传统第二代药物洗脱支架的长期随访：随机对照试验的系统评价和荟萃分析。
Eur Heart J. 2021 Jul 15;42(27):2643-2654. doi: 10.1093/eurheartj/ehab280.
9
BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.生物基质支架与奥西罗支架治疗冠状动脉疾病的多中心、随机、开放标签研究。
Circ Cardiovasc Interv. 2023 Jan;16(1):e012307. doi: 10.1161/CIRCINTERVENTIONS.122.012307. Epub 2022 Dec 7.
10
Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.ST 段抬高型心肌梗死患者中超薄支架可生物降解与薄支架持久聚合物药物洗脱支架的复杂经皮冠状动脉介入治疗：来自 BIOSTEMI 随机试验的亚组分析。
Catheter Cardiovasc Interv. 2023 Mar;101(4):687-700. doi: 10.1002/ccd.30600. Epub 2023 Feb 19.
引用本文的文献
1
Ultrathin-strut stents - towards zero stent-related events?超薄支架——能否实现零支架相关事件？
AsiaIntervention. 2025 Jul 30;11(2):e97-e98. doi: 10.4244/AIJ-E-25-00004. eCollection 2025 Jul.
本文引用的文献
1
Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects.超细支撑与细支撑支架在临床前和临床研究对象中的愈合情况及结果
EuroIntervention. 2024 May 20;20(10):e669-e680. doi: 10.4244/EIJ-D-23-00563.
2
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.超薄型与传统第二代药物洗脱支架的长期随访：随机对照试验的系统评价和荟萃分析。
Eur Heart J. 2021 Jul 15;42(27):2643-2654. doi: 10.1093/eurheartj/ehab280.
3
Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.小血管病变患者中应用薄支架、超薄支架或极薄支架药物洗脱支架的临床结局：随机 BIO-RESORT 试验的预设分析。
JAMA Cardiol. 2019 Jul 1;4(7):659-669. doi: 10.1001/jamacardio.2019.1776.
4
The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents.可生物降解聚合物药物洗脱支架难以捉摸的晚期益处
Circulation. 2019 Jan 15;139(3):334-336. doi: 10.1161/CIRCULATIONAHA.118.038378.
5
Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.新一代超小径药物洗脱支架与上一代较厚支架药物洗脱支架治疗冠状动脉疾病的比较。
Circulation. 2018 Nov 13;138(20):2216-2226. doi: 10.1161/CIRCULATIONAHA.118.034456.
6
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.在高风险介入治疗环境中，支架的早期血栓形成是由支架设计和部署驱动的，并受到聚合物药物涂层的保护。
Circulation. 2011 Apr 5;123(13):1400-9. doi: 10.1161/CIRCULATIONAHA.110.003210. Epub 2011 Mar 21.
7
Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.西罗莫司或紫杉醇洗脱支架重叠部位延迟愈合和持续性炎症的差异反应
Circulation. 2005 Jul 12;112(2):270-8. doi: 10.1161/CIRCULATIONAHA.104.508937. Epub 2005 Jul 5.
Zotero 插件